American International Group’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

American International Group’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-206,358	Closed	-$27.2K	–	3195
2020 Q4	$27.2K	Sell	206,358 -181	-0.1%	-$16K	0.1%	153
2020 Q3	$9.86M	Sell	206,539 -149	-0.1%	-$6.7K	0.05%	358
2020 Q2	$9.85M	Buy	206,688 +17	+0%	+$791	0.05%	352
2020 Q1	$10.1M	Sell	206,671 -385	-0.2%	-$19.6K	0.06%	277
2019 Q4	$11.9M	Buy	207,056 +68	+0%	+$3.37K	0.05%	345
2019 Q3	$7.45M	Sell	206,988 -49	-0%	-$1.91K	0.03%	554
2019 Q2	$6.43M	Sell	207,037 -38,325	-16%	-$1.04M	0.03%	621
2019 Q1	$5.75M	Buy	245,362 +5,586	+2%	+$89.6K	0.02%	670
2018 Q4	$3.3M	Sell	239,776 -36	-0%	-$454	0.01%	846
2018 Q3	$2.39M	Buy	+239,812	New	+$3.94M	0.01%	976

American International Group's EIDX Position: Q1 2021 in Review

American International Group sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 206,358 shares — an estimated $27.2K sold.

American International Group first reported a position in EIDX in Q3 2018 and held it in 10 quarters. The position peaked at $11.9M in Q4 2019. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

American International Group reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
American International Group sold 206,358 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $27.2K.
American International Group first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2018 and held it in 10 quarters.
American International Group's Eidos Therapeutics, Inc. Common Stock position peaked at $11.9M in Q4 2019.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on American International Group's 13F filing for Q1 2021, filed 7 May 2021.